The Kaplan Thaler Group, a NYC based ad agency and client of Brainchild Studios, was tasked with developing the brand identity for a new ADHD drug being brought to market by Shire Pharmasuticals. Brainchild Studios was brought in to tackle the design of the brand mark. At the time the actual name of the product was still in flux (eventually to be called Vyvanse). 2 different names needed to be explored with the understanding that even they were not guarenteed. One of the biggest challenges was the need for the logotype to be flexible enough that the letterforms could be swopped out once a name was approved. Below is a portion of one of the later phases of the exploration. Fonts and concepts had been narrowed down at this point and a color scheme committed to.
WHAT IS ADHD?
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common mental disorders affecting children. ADHD also affects many adults. Symptoms of ADHD include inattention (not being able to keep focus), hyperactivity (excess movement that is not fitting to the setting) and impulsivity (hasty acts that occur in the moment without thought).
An estimated 8.4 percent of children and 2.5 percent of adults have ADHD. ADHD is often first identified in school-aged children when it leads to disruption in the classroom or problems with schoolwork. It can also affect adults. It is more common among boys than girls.